Eli Lilly has decided to terminate its partnership with Adocia for the development of BioChaperone Lispro, an ultra-rapid insulin for diabetes.
Despite results from 6 clinical studies indicating that Adocia’s ultra-rapid insulin performs better than Eli Lilly’s Humalog, the big American pharma has decided to terminate its collaboration with the French biotech. As part of this licensing partnership, Eli Lilly had already paid more than €56M ($60M) during development. But the rights will now get back to the biotech at no cost.
Gérard Soula, CEO of Adocia, expressed surprise and disappointment saying, “We are convinced that BioChaperone Lispro can improve the lives of people with diabetes and Adocia will continue to prepare launch of Phase III clinical trials while looking for a new partner.”
The product in question uses Adocia’s Biochaperone technology, which forms a complex with the desired drug to protect it from degradation and enhance its performance. In the case of insulin, this technology makes absorption faster, which improves the level of control patients with both Type 1 and Type 2 diabetes have over their blood sugar.
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes kit) and news about food suitable for a diabetic diet. Go to the top of this page to sign up – we just need your email address.